Dr. Anglesio's research has focused primarily on defining subtypes of ovarian cancer. In particular, genomic and protein-based biomarker studies that differentiate types and subtypes of each ovarian cancer histology. Most recently he has been focused on uncovering the mechanism through which endometriosis may become malignant and progress into either clear cell or endometrioid ovarian cancer. In 2017 Dr. Anglesio's group was first to provide evidence that roughly 1/3 of endometriosis frequently harbours cancer-driver mutations, and that these mutations are restricted to only one of two cell types that make up endometriosis.


Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging
Modern Pathology
Naveena Singh and Asma Faruqi and Friedrich Kommoss and W Glenn McCluggage and Giorgia Trevisan and Janine Senz and Amy Lum and C Blake Gilks and Michael Anglesio
DOI: 10.1038/modpathol.2017.159

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Nature Genetics
Yi Kan Wang and Ali Bashashati and Michael S Anglesio and Dawn R Cochrane and Diljot S Grewal and Gavin Ha and Andrew McPherson and Hugo M Horlings and Janine Senz and Leah M Prentice and Anthony N Karnezis and Daniel Lai and Mohamed R Aniba and Allen W Zhang and Karey Shumansky and Celia Siu and Adrian Wan and Melissa K McConechy and Hector Li-Chang and Alicia Tone and Diane Provencher and Manon de Ladurantaye and Hubert Fleury and Aikou Okamoto and Satoshi Yanagida and Nozomu Yanaihara and Misato Saito and Andrew J Mungall and Richard Moore and Marco A Marra and C Blake Gilks and Anne-Marie Mes-Masson and Jessica N McAlpine and Samuel Aparicio and David G Huntsman and Sohrab P Shah
DOI: 10.1038/ng.3849


Influence of "cancer driver" somatic mutation on the immune microenvironment of endometriosis and endoemtriosis-associated ovarian cancers

Prevelance of "cancer driver" somatic mutations in endometriosis subtypes, as well as the association of somatic mutations with clinical factors such as pain


CIHR Early Career Investigator Operating Grant: Endometriosis Microenvironment: Influence of "Cancer-Driver" Mutations

NIH R37 Project Grant (Co-Applicant): High-throughput Epigenomic Mapping of Regulatory Elements in Ovarian Cancer at Basepair Resolution

CIHR Project Grant (Co-Pl): Sexual Pain in Endometriosis: Role of Somatic Mutations and Local Neurogenesis

Honours & Awards

2016/5 - Department of Pathology and Laboratory Medicine Award for Excellence in Mentoring, University of British Columbia

2019/1- Most impactful paper published in 2017 from the Columbia Hospital for Women Research Foundation (CHWRF) with reference to: Anglesio et al. N Eng J Med 2017. Cancer-Associated Mutations in Endometriosis without Cancer